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Abstract 
Cancer of the esophagus is the 8th most common cancer form in the world, with approximately 460.000 new 
cases annually. It is often diagnosed at a late stage, associated with severe morbidity and a poor prognosis, 
why treatment frequently has a palliative aim to control the main symptom, i.e. dysphagia. The present thesis 
aims to explore some of the questions related to and eventually improving the management of these patients.  
 
The two most common palliative strategies today, i.e. stent-treatment and brachytherapy, were compared in a 
randomised trial enrolling 65 patients with incurable cancer of the esophagus or gastro-esophageal junction 
(GEJ). Stent-treatment was found to offer a more prompt effect on dysphagia and was more cost-effective 
than brachytherapy. On the other hand, brachytherapy offered a less pronounced deterioration of health-
related quality of life (HRQL) and an equal relief of dysphagia after 3 months, why it gives a viable 
alternative in patients with a longer survival (Paper I+II). 
 
To evaluate if survival can be better predicted, 96 patients with newly diagnosed incurable cancer of the 
esophagus or GEJ were included and their clinical variables and HRQL data analyzed. In a univariate 
analysis, Karnofsky Index, M-stage, tumor-stage, CT derived size assessment of the primary tumor and 10 of 
25 scales and items of the HRQL questionnaires (EORTC QLQ-C30 and QLQ-OES18) were found to relate 
to survival. However, in a multivariate analysis, only M-stage, physical functioning, fatigue and reflux scale 
were found to be independent predictors. Internal validation of the established predictors showed a high level 
of reliability (Paper III). 
 
Psychiatric morbidity in patients with cancer of the esophagus or GEJ was screened at diagnosis and during 
one year thereafter. We observed anxiety disorder and depression in 94 patients in all stages of the disease 
using the HADS questionnaire. Anxiety and/or depression were found to be common at diagnosis (42% of 
the patients), regardless of sociodemographic background, tumor-stage or therapy given. The proportion of 
patients with anxiety disorder decreased during the first two months compared to at diagnosis (34%), while 
the proportion of patients with depression was comparatively stable over time (29% at diagnosis). 
Depression was, however, more common among patients who died during the study period compared to the 
survivors (Paper IV). 
 
The long-term clinical and functional outcomes of radical surgery with pharyngolaryngoesophagectomy and 
jejunal transposition following chemoradiotherapy in patients with proximal esophageal or hypopharyngeal 
cancer were evaluated. Promising long-term results with regard to survival were observed. In addition, a 
generally good HRQL and mild dysphagia was found, in spite of a generally poor speech valve function and 
disturbed bolus-passage according to radiological evaluation (Paper V+VI). 
 
 
Key words: brachytherapy, dysphagia, esophageal neoplasms, free jejunal graft, health economic evaluation, 
palliative care, prediction, psychiatric morbidity, radiographic evaluation, stent, survival, quality of life, 
voice prosthesis.  
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Abbreviations 
AJCC American Joint Committee on Cancer 
CI Confidence Interval 
CT Computer Tomography 
EORTC European Organisation for Research and Treatment of Cancer 
EUS Endoscopic Ultrasound 
GEJ Gastro-Esophageal Junction 
GERD Gastro-Esophageal Reflux Disease 
Gy Gray 
HADS Hospital Anxiety and Depression Scale 
HDR High Dose Rate 
HPV Human Papilloma Virus 
HRQL Health Related Quality of Life 
ITT Intention-To-Treat 
KPSSI/KPS Karnofsky Performance Status Scale Index 
LES Lower Esophageal Sphincter 
MRI Magnetic Resonance Imaging 
PEJ Pharyngo-Esophageal Junction 
PET Positron Emission Tomography 
PLE Pharyngo-Laryngo-Esophagectomy  
PP Per-Protocol 
SEMS Self-expandable Metal Stent 
SD Standard Deviation 
TNM Tumor, Node, Metastases 
QoL Quality of Life 
QLQ-C30 Quality of Life Questionnaire-Core 30 
QLQ-OES18 Quality of Life Questionnaire-Oesophageal module 18 
UICC Union Internationale Contre le Cancer 
WDS Watson Dysphagia Score 
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Introduction 
Cancer is the Latin word for crab. The word has been used to depict 
malignancy since ancient times, possibly because of the crab-like persistence 
a malignant tumor sometimes shows in grasping the tissues it invades, or 
because of the form of some cancerous lesions that actually reminds of the 
form of a crab. Hippocrates (Figure 1), who described cancer in detail, used 
the Greek terms "carcinos" and "carcinoma" to refer to chronic ulcers or 
growths that seemed to be malignant tumors1. Later on, a Roman physician 
by the name Celsus (28 BC - 50 AC) translated the Greek word "carcinos" 
into the word "cancer". Hence, the word "cancer" is very old. However, it is 
used for a large number of different diseases with a variety of etiologies and 
appearances that require different cares and treatments. 
Figure 1. Hippocrates (460-370 BC) 
That cancer can emerge also in the esophagus has been known since 
centuries and was recognized as a cause of dysphagia by the Chinese about 2000 years ago2. Surgical 
treatment of esophageal cancer has been performed since the end of the 19th century, and initially, the goal 
was mainly to achieve palliation through “by-passing” the site of the tumor so that nutrition could be 
preserved. More sophisticated methods were developed during the 20th century, also aiming at eradicating 
the tumor burden and finding suitable substitutes for the removed part of the esophagus. Several prominent 
surgeons have contributed to this progress, among those Dr César Roux (1857-1934) who in 1906 described 
the use of the jejunum as a replacement for the esophagus3 and Dr Iwor Lewis (1895-1982) who in 1948 
described gastric mobilization and jejunostomy followed by a right thoracotomy and immediate anastomosis 
as a one stage procedure4.  
The advancement within the oncological field has resulted in chemo- and radiotherapy as optional 
treatment strategies for cancer of the esophagus or in addition to surgery. Radiation therapy has been 
practiced in cancer treatment ever since Wilhelm Conrad Röntgen (1845-1923) discovered the x-rays in 
1895, and the modern era of chemotherapy can be traced back to the discovery of nitrogen mustard during 
World War II5. During the last decades, development of new cytotoxic agents as well as modification of 
radiation schedules, e.g. hyperfractionation, with better tumor-specific distinctiveness and milder side 
effects, have greatly contributed to a wider use in esophageal cancer treatment. The start of use of high dose 
rate (HDR) endoluminal brachytherapy in the end of the 1980s has resulted in an optional treatment strategy 
for palliation of these patients6. Self-expandable metal stents (SEMS) became commercially available in the 
beginning of the 1990s and has revolutionized the treatment of malignant strictures within the esophagus7.  
Nevertheless, in spite of this progress, esophageal cancer is still often diagnosed at a much too late 
stage, is related to severe morbidity and a poor prognosis with an overall 5-year survival rate between 10 and 
15%8. In the majority of cases, distant metastases are already present at diagnosis and, as a consequence, 
palliative treatment is the only option available9. Hence, much effort still has to be done to improve the 
situation for these patients.  
Epidemiology and risk factors 
Today, cancer of the esophagus is assessed to be the 8th most common cancer form in the world, with 
approximately 460.000 new cases annually10. The incidence varies between different geographical regions, 
with especially high rates in Asia, Africa and South-America, and in some parts the rates are as high as 200 
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per 100.000 inhabitants and year. For Western Europe and Northern America, the incidence rates are around 
5-10 per 100.000, with prevalence rates close to this number indicating a short survival time after diagnosis. 
Globally, esophageal cancer is the sixth cause of cancer-related death10. 
There are mainly two different types of esophageal cancer, i.e. adenocarcinoma and squamous cell 
carcinoma, and even though they share many characteristics, the risk factors for the two types have proved to 
be rather diverse. Adenocarcinoma of the esophagus and the gastro-esophageal junction (GEJ) has demon-
strated a rapid increase in incidence during the last decades, especially among white males within Western 
Europe and Northern America11. The reasons for this are still ambiguous, however, a connection to an 
increased prevalence of known risk factors such as gastro-esophageal reflux-disease (GERD), Barrett’s 
esophagus and obesity has been proposed9,12,13. Furthermore, the reduced prevalence of Helicobacter pylori 
infections (mainly due to medical eradication therapy), as well as an augmented use of medications that 
affect the tonus of the lower esophageal sphincter (LES) (e.g. anticholinergics and benzodiazepines), have 
been suggested as potential causes of an increased incidence of esophageal adenocarcinoma9. The observed 
male predominance is, however, not explained by these hypotheses. 
Squamous cell carcinoma of the esophagus, on the other hand, has demonstrated relatively stable 
incidence rates within most geographical regions during the last decades and, what is more, a tendency 
towards declining rates has been reported for several countries including Sweden during the last few years14. 
Established risk factors for this type of cancer are smoking, excessive alcohol consumption, dietary factors, 
low socioeconomic status and a previous history of head-and-neck cancer9. Moreover, a recent field of 
investigation is the association between human papilloma virus (HPV) infections and squamous cell cancer 
of the esophagus. However, high risk HPV-types detection rates are greatly variable in different geographical 
areas of the world and may have a conjunction with socioeconomic status15. As for adenocarcinoma and 
many other cancer forms, high age is a risk factor also for squamous cell carcinoma of the esophagus. In 
addition, esophageal cancer is three times more common in men than in women16. 
Symptoms, diagnosis and staging 
Approximately 90% of patients with esophageal cancer present with 
dysphagia9. Many patients also have a history of weight loss, 
anemia, and/or retrosternal pain, while hoarseness and dyspnea may 
be a sign of overgrowth to adjacent structures. Frequently, symp-
toms have been present for 6 months or more, possibly due to a 
poor awareness among the general population of dysphagia as a 
symptom of a potentially lethal disease17. Endoscopy with biopsy 
for histological examination verifies the diagnosis and computer-
ized tomography (CT) scans of the neck, thorax and abdomen, 
endoscopic ultrasound examination (EUS) and in some cases 
bronchoscopy and/ or laparoscopy of the abdomen are part of the 
staging procedure. Determination of the exact length, invasiveness 
and localization of the tumor is important for a correct decision 
upon treatment-strategy (Figure 2)18. 
 
10 Figure 2. Localization of esophageal cancer
(UICC, TNM Atlas, 5th ed, 2004). 
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Primary tumor (T-stage)  
TX Primary tumor can not be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor invades lamina propria or submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades adventitia 
T4 Tumor invades adjacent structures 
Regional lymph nodes (N-stage)  
NX Regional lymph nodes can not be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant metastases (M-stage)  
MX Distant metastases can not be assessed 
M0 No distant metastases 
M1 Distant metastasis 
UICC-stage T N M 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T2 N0 M0 
 T3 N0 M0 
Stage IIB T1 N1 M0 
 T2 N1 M0 
Stage III T3 N1 M0 
 T4 NX-1 M0 
Stage IVA T1-4 NX-1 M1a 
Stage IVB T1-4 NX-1 M1b 
Table 1a. TNM classification of eso-
phageal cancer (UICC, TNM Classification 
of Malignant Tumors, 6th ed, 2002). 
Table 1b. Staging of esophageal cancer 
(UICC, TNM Classification of Malignant 
Tumors, 6th ed, 2002). 
Staging is performed according to the TNM-classification and the 
UICC (Union Internationale Contre le Cancer) or AJCC (American 
Joint Committee on Cancer) staging system (Table 1a+b)19. For T- 
and N-stage, EUS has proved to be the most reliable staging tech-
nique to date, with an accuracy between 80 and 90%20. However, 
the development of other non-invasive staging modalities, such as 
high-resolution CT, magnetic resonance imaging (MRI) and 
positron emission tomography (PET) may result in a diminishing 
use of EUS as a staging-tool for esophageal cancer. Although the 
TNM-staging has many values and is currently considered “the 
golden standard” for classification of esophageal cancer, its 
reliability as a predictor for survival has repeatedly been 
questioned21,22. Whether this eventually will result in a novel 
classification system with better clinical implications is, however, a 
matter of speculation.  
Treatment with a curative intent 
Patients without metastases or tumor-invasion into adjacent 
structures (T1-3N X-1M 0) are normally offered treatment with a 
curative intent. Giving that sufficient outcomes on a bicycle exercise 
test and a spirometry test have been achieved, this treatment typi-
cally consists of radical surgery including lymphadenoidectomy 
with or without preoperative chemoradiotherapy9. Depending on the 
tumor-location, different surgical approaches are practiced. Tumors 
of the proximal intrathoracic or mid-thoracic part of the esophagus 
can be handled by total esophagectomy including thoracotomy and 
substitution with gastric tubularization or colonic transposition. 
Distal tumors including the GEJ are usually treated by partial 
esophagectomy, including substitution with gastric tubularization or 
by an esophago-jejunostomy (Roux-en-Y). The latter intervention is 
mainly used for cancers of the GEJ type III (subcardial)23 and often 
performed by a transhiatal approach23. Although survival rates are 
unsatisfactory even after curatively intended therapy, recent data suggest an improvement for both 
histological types for Sweden in the last few years. For adenocarcinoma, the 5-year relative survival rate 
during 1990-96 was 13.7%, while the corresponding figure for squamous cell carcinoma was 8.9%24. A 
better selection of surgical candidates, as well as an enhancement of the entire treatment arsenal including 
the surgical procedures, has been emphasized as potential explanations to this trend.   
Palliative treatment 
Palliation is the primary aim in the majority of patients with advanced cancer of the esophagus and the GEJ. 
However, as these patients have a complex symptomatology, multiple aspects have to be considered to 
comprehensively address the patient’s overall situation6,7. The relief of dysphagia, with a minimum of side 
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Figure 4. High-dose rate (HDR) 
brachytherapy. 
Figure 3. Self-expandable metal stent 
(SEMS). 
effects and interventions, is an objective of high priority and a variety of 
palliative procedures have been advocated. Endoscopic placement of 
SEMS (Figure 3) has become the most widely practiced treatment, in 
part due to the comparatively simple technique and rapid effect on 
dysphagia 7,25. Complications are reasonably infrequent and mainly 
consist of stent-migration, food impaction, perforations and fistulae26. 
Stent occlusion, due to tumor or granulation tissue growth, is, however, a 
matter of concern and re-intervention rates has been described in as 
much as 27% of patients27. Endoluminal brachytherapy (Figure 4) is an 
alternative with some promising results28, but requires access to rather 
sophisticated equipment, e.g. a radiation source, and is normally 
available at high-volume centers only29. A drawback for laser therapy as 
a palliative regime has been the transitory effect on dysphagia and need 
for repeated interventions30, whereas photodynamic therapy (PDT) is 
rather costly and associated with side effects such as photosensitivity31. The use of external radiotherapy 
alone or in combination with chemotherapy has been questioned due to the delay in relief of dysphagia and 
severe side effects6.  
Aspects on patient’s quality of life may be considered to be of special importance when the treatment 
regime is strictly palliative. Apart from the direct effects of the dysphagia-relieving interventions, such 
factors as pain therapy, nutritional support and psychological care from 
both health care providers and family members are important to the 
quality of the patient’s remaining life. In recent years, health-related 
quality of life (HRQL) questionnaires have been developed to enable 
longitudinal evaluation of patient’s quality of life during and after treat-
ment for cancer32, including patients with esophageal cancer33. The value 
of utilizing these instruments, not only for aims of research but also as a 
tool in clinical practice, has been emphasized by many34-37. Another topic 
of interest, especially when considering treatment strategies with similar 
clinical outcomes, is the health economic consequences. There is a 
constant need for controlled randomized clinical trials, including all these 
aspects, to offer guidance for the clinician in the choice between various 
palliative therapeutic modalities38.  
Cancer of the pharyngo-esophageal junction 
Cancer of the hypopharynx and the proximal part of the esophagus are often considered together due to their 
equivalent clinical characteristics and therapeutic problems. Histologically, in the vast majority of cases, they 
are both squamous cell carcinomas and also share the same main risk factors, i.e. excessive alcohol con-
sumption and smoking9. Rather frequently, cancer is present at both sites either due to continuous over-
growth or due to two synchronous primary tumors. Hence, cancer of the hypopharynx and the proximal part 
of the esophagus are often referred to as cancer of the pharyngo-esophageal junction (PEJ)39. 
For patients with non-disseminated disease, radical surgical intervention with or without the addition of 
chemoradiotherapy is to date considered the first line of treatment by many40-43. Nevertheless, surgical 
treatment of patients with cancer of the PEJ remains a great challenge and several different techniques have 
been applied throughout the years, including the use of myocutaneos flaps, colon transposition and reversed 
gastric tubes40,43-49. Circumferential pharyngo-laryngo-esophagectomy (PLE) and reconstruction with a free 
vascularized jejunal transplant has gained a wide acceptance world-wide, in part due to improvements in the 
microsurgical technique, an acceptable procedure-related morbidity and mortality and in many cases a 
promising functional long-term outcome41,43,45,46,50,51. 
Non-surgical treatment of these patients, such as chemoradiotherapy alone, may be associated with 
several disadvantages such as; severe toxicity, insufficient eradication of the primary tumor, a high rate of 
tumor recurrence, persisting dysphagia and no survival gain52,53. By-pass surgery as an option for palliation, 
associated with high rates of peroperative mortality and morbidity6, has to a great extent been replaced by 
stent placement. Although complications and technical difficulties exist also for the latter strategy, recent 
studies report encouraging results54-56. However, the majority of studies performed on patients with cancer of 
the PEJ are retrospective analyses consisting of a broad mixture of different tumor-sites, tumor-stages and 
therapeutic interventions (Table 2). Consequently, as long as no results from randomized controlled trials 
between various treatment options for these patients exist, it is difficult to emphasize the superiority of one 
regime compared to the other. 
Table 2. Retrospective studies presenting results after pharyngo-laryngo-esophagectomy (PLE) and reconstruction with a visceral 
interposition. 
Ref No 
pat 
Main 
Site  
Recon- 
struction 
C/RT Postop 
mortality 
Graft 
failure 
Stric- 
tures 
Fistula 1yr 
surv 
3yrs 
surv 
5yrs 
surv 
Timon44 51 H+E Sto/Col Mix 25%    36%  8% 
Triboulet42 209 H+E Sto/Jej/Col Mix 5% 6% 8% 22% 62% 32% 24% 
Nakatsuka46 70 H+E Jejunum RT 2% 7% 9% 4%    
Shilling40 18 H Stomach RT 11%   6% 82% 72% 60% 
Ullah47 26 H+E Stomach - 12%  19% 15% 65% 35% 26% 
Oniscu48 20 H Jejunum Mix 0% 0% 30% 5% 52% 33% 18% 
Laterza49 167 H+E Sto/Jej/Col Mix 9% 2%  18%   17% 
Jones41 90 H Jejunum RT 4% 19% 12% 11% 70% 50% 42% 
Ferguson51 18 H+E Jejunum RT  6% 11% 33% 22% 11% 0% 
Shirakawa43 54 H+E Jejunum - 0% 9%     47% 
         H=hypopharynx; E=proximal esophagus; Sto=stomach; Jej=jejunum; Col=colon; C/RT=chemo/radiotherapy; Surv=survival 
Cancer of the gastro-esophageal junction 
Tumors which have their center within 5 cm proximal or distal to the anatomical cardia are usually cate-
gorized as cancers of the gastro-esophageal junction (GEJ). Although some controversies still exist, epi-
demiological, clinical and pathological data support a sub-classification of these cancers. Such a sub-
classification, today considered as the golden standard, was presented by Siewert and Stein in 199857. 
Adenocarcinoma of the distal esophagus (cancer of the GEJ Type I) usually arises from an area with 
specialized intestinal metaplasia (Barrett’s esophagus) and typically infiltrate the GEJ from above. This type 
of cancer has been associated with, as opposed to the other types, a significantly marked male preponder-
ance, the common presence of a hiatal hernia and a long history of GERD. True carcinoma of the cardia 
(cancer of the GEJ Type II) arises from the cardiac epithelium or short segments with intestinal metaplasia at 
the GEJ, while subcardinal gastric carcinoma (cancer of the GEJ Type III) infiltrates the GEJ and distal 
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esophagus from below23. The latter type is associated with a higher extent of diffuse tumor growth and a 
worse outcome after surgical resection compared to Type I, while Type II has characteristics somewhere in 
between the two other tumor types. For cancer of the GEJ Type I, II and III, the 5-year survival rates after 
surgical resection are approximately 45%, 40% and 25%, respectively58. 
Apart from the localization, the three types of cancer of the GEJ also shows different patterns of 
lymphatic spread and are accordingly treated with different approaches. The optional surgical strategies 
consist of abdomino-thoracic en bloc esophago-gastrectomy, subtotal esophagectomy with resection of the 
proximal stomach, total gastrectomy with transhiatal resection of the distal esophagus or a more limited 
resection of the GEJ. Consequently, various extent of lymphadenoidectomy is performed23.  
Palliation of patients with cancer of the GEJ constitutes a particular problem. Higher complication rates 
after stent insertion has been reported for these patients compared to patients with cancer of more proximal 
parts of the esophagus25. Such complications typically consist of stent-migrations, problems with reflux, 
ulcerations and bleedings. In addition, the quality of swallowing after stent-insertion has been reported to be 
inferior. This has partly been explained by an angulation of the stent at the GEJ resulting in a disturbed 
bolus-passage25. 
Health-related quality of life 
During the last three decades, an increasing awareness of the importance of evaluating the cancer patient’s 
quality of life has been observed. This has been facilitated by the development of various validated 
questionnaires that focus both on the general health issues as well as cancer specific and tumor-site specific 
problems. General questionnaires typically deal with physical, psychological and social functioning and can 
be applied to any patient group or to the general population. One of the most used general questionnaire is 
the 36-item short-form health survey (SF-36), first presented in 199259. Cancer specific questionnaires 
mainly focus on functions, symptoms and various side effects of treatment. Examples of such well-
established questionnaires are the European Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire Core 30 (EORTC QLQ-C30)32 (Appendix 1) and the Functional Assessment of Cancer 
Therapy scale (FACT-G)60. Tumor-site specific questionnaires, such as the EORTC esophageal module 
(EORTC QLQ-OES18)33 (Appendix 2), aim to measure functional problems, as well as side effects of 
treatment, for a specific cancer type of interest. 
The prognostic value of various clinical data at diagnosis, such as patient’s age, performance status or 
tumor-characteristics, varies between different cancer types and has been questioned21,22. The outcome of  
HRQL questionnaires has, however, been found to own predictive properties on survival, both in patients 
with early and advanced cancer36,61, and also in patients with esophageal cancer35. Self-reported quality of 
life data from individual cancer patients have shown not only to harmonize with the disease course but even 
better reflect the functions and problems/symptoms than other biomedical indicators37. This could be due to, 
for instance, the occurrence of micrometastatic disease states that is not detected by radiological 
examination35. Some authors even suggest that HRQL outcomes better outlines the disease states than what 
the patient actually tells the doctor37. In addition, others have found doctors to be systematically too 
optimistic when predicting survival in terminally ill patients61. Consequently, HRQL instruments offer a 
large variety of implications and should be generously incorporated in clinical trials involving cancer 
patients.  
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Psychiatric morbidity 
Psychiatric morbidity among cancer patients has also attracted an increasing interest in recent years. This has 
been promoted by the development of new therapeutic modalities for both curative and palliative treatment, 
increasing awareness of the importance of cancer patients’ quality of life, but also by the development of 
more sophisticated methods for screening for mental distress62-64. Most of the available screening question-
naires have been developed to screen for anxiety and depression disorders. In 1983, Zigmond and Snaith 
presented one of the most used instruments so far, the Hospital Anxiety and Depression Scale (HADS) 
questionnaire63 (Appendix 3). 
Anxiety disorders encompass several subgroups, e.g. panic disorders, obsessive-compulsive disorders, 
post-traumatic stress disorders and different phobias, including social anxiety disorder. In the general 
population, the lifetime prevalence rate for anxiety disorders ranges between 3 and 12 percent and is 
approximately twice as common among women as among men65. Major depressive disorders account for 
more than 4 percent of the overall global disease burden, have a lifetime prevalence rate between 5 and 10 
percent and is highly associated with recurrent episodes66. Among patients with cancer, a high prevalence of 
anxiety disorder and depression has been found in several cross-sectional and longitudinal studies, e.g. in 
patients with cancer located in the head and neck, breasts and the gastro-intestinal tract67-74. 
A recent register study, performed by the Swedish National Board of Health and Welfare, found an 
increased risk for suicide among patients with cancer compared to the general population75. A correlation 
between cancer type with a poor prognosis and an increased risk for suicide was reported, and cancer of the 
esophagus was found to be among the forms of cancer associated with the highest risk of all sites investi-
gated. Moreover, the occurrence of psychiatric morbidity and hence the potential need for psychological 
support may vary over time after diagnosis. Great concern and attention is thus warranted for these patients’ 
mental health, not only at diagnosis but also during treatment.  
Health-economics  
Health economics is a branch of economics concerned with issues related to the scarcity in the allocation of 
health and health care. Preferably, health economic evaluation should be carried out alongside clinical trials 
in order to build in appropriate data as an integrated part of the study76,77. Topics related to various aspects of 
health economics include the measurement of health status, the production of health care, the demand for 
health services, health economic evaluation, health insurance and the analysis of health care markets, health 
care financing, and hospital economics. However, the costs can be assessed in many different ways and thus 
with different health economic results. 
A matter of importance is to determine from whose viewpoint an economic evaluation is to be carried 
out. It may be based on the individual patient’s, the hospital’s, the government’s or the society’s point of 
view76. The latter is usually preferred since this will include all the costs and benefits, no matter to whom 
they accrue. Secondly, the costs can be assessed from consumed resources or from charges. The former 
assessment, also known as “micro-costing”, includes detailed measurements of hospital investments, main-
tenance of equipment, salaries, material-costs, housing, overhead costs etc., and is perhaps the most accurate 
approach77. It is, however, relatively work- and time-consuming and is mainly used in large clinical trials. 
When costs are assessed from charges, the costs are calculated from bills from the providers of health care 
services. For this approach to be consistent, the gap between the costs of consumed resources and the charges 
has to be small.  
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Four main approaches to health economic evaluation exist. These include cost-minimization analysis (used 
when the clinical outcome is believed to be the same between groups), cost-effectiveness analysis (the 
outcome is measured in natural units, e.g. life years gained), cost-utility analysis (the outcome is linked to 
subjective data, e.g. HRQL) and cost-benefit analysis (the outcome is valued in monetary terms)76. Each of 
these approaches involves identification, measurement and, where appropriate, evaluation of the costs and 
consequences of the options under review. The appropriate method of economic evaluation will depend on 
the context in which choices need to be made.  
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General and specific aims of this thesis 
The general comprehensive aim of this thesis was to explore questions related to the management of patients 
with esophageal cancer. 
 
To achieve this, the following specific aims were defined: 
 
• To compare endoluminal brachytherapy with endoscopic stent placement over time in newly 
diagnosed patients with advanced cancer of the esophagus or the GEJ. The patient’s HRQL, 
psychiatric morbidity and health-economic aspects were the primary outcomes and, secondly, other 
parameters relevant to the management of these patients were addressed, such as the level of 
dysphagia control, adverse events and survival. 
 
• To assess the value of clinical data, CT-derived tumor size assessment and HRQL data at diagnosis 
for prediction of the remaining lifetime in patients with newly diagnosed incurable cancer of the 
esophagus or the GEJ.  
 
• To prospectively and longitudinally screen for psychiatric morbidity in a group of patients with all 
stages of newly diagnosed cancer of the esophagus or the GEJ. A secondary aim was to explore 
potential relationships between the patients’ mental health and their sociodemographic and clinical 
data, as well as the treatment regime applied. 
 
• To evaluate functional long-term outcomes in patients who have undergone circumferential PLE due 
to hypopharyngeal or proximal esophageal cancer and reconstruction with a free vascularized jejunal 
transplant combined with a voice prosthesis. 
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Methodological considerations 
This thesis summarizes six studies incorporating different groups of patients, treatment modalities and 
investigational methods. Study I and II evaluated different aspects on treatment in a group of 65 patients with 
incurable cancer of the esophagus and the GEJ, while study III analyzed potential factors predictive of 
survival in 60 of the 65 patients included in study I and II plus 36 patients from another trial with the same 
inclusion-criteria. In study IV, we screened for psychiatric morbidity in 94 other patients with all stages of 
cancer of the esophagus or the GEJ and in study V and VI, the long-term results of the first 16 patients 
treated with radical surgery due to cancer of the PEJ were evaluated.    
Study-designs 
In study I and II, a prospective, randomized, parallel group, multicenter study was conducted to compare 
SEMS-treatment and fractionated HDR brachytherapy in patients with incurable cancer of the esophagus or 
the GEJ. Randomization was performed in a 1:1 fashion by a validated computer-based algorithm stratifying 
for age, sex, grade of dysphagia, tumor histology and site, and was conducted by The Regional Cancer 
Register of Göteborg. Primary outcomes were patient’s HRQL (study I) and health economy (study II). 
Secondary outcomes were effect on dysphagia, adverse events and survival. A per-protocol (PP) and an 
intention-to-treat (ITT) analysis were performed in study I and II, respectively. The patients were followed 
until death. 
In study III, prospectively collected data from two randomized controlled trials on patients with 
incurable cancer of the esophagus or the GEJ were analyzed in order to evaluate factors predictive of 
survival. In the first trial, patients were randomized to treatment with either SEMS or endoluminal brachy-
therapy (study I+II). In the second trial, patients were randomized to treatment with SEMS either with or 
without an antireflux valve78. Analyzes incorporated various clinical data, HRQL data at inclusion from the 
EORTC QLQ-C30 and QLQ-OES18 questionnaires and results from CT derived tumor size assessment. The 
latter was, however, done from routine CT examinations obtained for staging purposes before treatment. 
In study IV, a prospective cohort study was set up to screen for psychiatric morbidity by means of the 
HADS questionnaire in patients with newly diagnosed, untreated cancer of the esophagus or the GEJ. 
Potential relationships between the patients’ mental health and their sociodemographic and clinical data, as 
well as the treatment regime applied were explored. The HADS questionnaire was completed at inclusion 
and 1, 2, 3, 6 and 12 months later. 
In study V, a retrospective, case-series evaluation of the long-term results of the first 7 patients who 
underwent PLE due to cancer of the PEJ at the Sahlgrenska University Hospital was performed, along with a 
presentation of pre-, per- and postoperative data including histopathological examination of the specimens. 
In study VI, a cross-sectional study including assessment of HRQL (EORTC QLQ-C30 and QLQ-OES18), 
voice quality and dysphagia (including Watson Dysphagia Score and radiological examination with an inter-
observer evaluation) of 10 survivors after PLE (partly the same patients as in study IV) was carried out. 
Comments 
This thesis includes several different study-designs indeed, including retrospective, cross-sectional and 
prospective ones. In the hierarchy of research designs, the results of randomized controlled trials are 
considered to be evidence of the highest grade, whereas observational studies are viewed as having less 
validity because they reportedly overestimate treatment effects79. Even so, different study-designs fulfill 
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different purposes. A major advantage of a randomized controlled clinical trial is the control over unknown 
confounders, i.e. factors that cannot be adjusted for since they are unknown. The outcomes can thereby often 
give direct implications in clinical practice. However, a drawback for a randomized control trial could be a 
low degree of generalizability, mainly due to the strict inclusion and exclusion criteria predetermined.  
Retrospective and cross-sectional studies mainly fulfill hypothesis-generating purposes, but are 
nonetheless important. In addition, it has been shown that no fundamental difference exist in conclusiveness 
between randomized and non-randomized trials as long as they are relatively small80. These aspects are 
relevant for many non-randomized studies performed in patients with esophageal cancer, since these patients 
are typically in a poor condition; have a short survival time and frequently, only a limited number of patients 
are available for inclusion.  
The pros and cons of PP- and ITT-analyses depend on the object of interest in a study, but normally, the 
ITT-principle is considered to be the most accurate way to present data. Both analyses were performed in 
study I, however, only the PP-analysis was presented in order to best describe the effects of the actual 
treatment given. No statistically significant differences in HRQL outcomes were found between the two 
methods of analysis. Accordingly, an ITT-analysis was preferred in study II in order to evaluate the health 
economic effects of a decision upon treatment with either SEMS or brachytherapy.  
Treatment procedures 
In study I and II, patients allocated to stent treatment were given a self-expandable Ultraflex® (Micro-
vasive®, Boston Scientific Corp.) metal stent with a length from 10 to 15 cm depending on the length of the 
tumor (Figure 3). The vast majority were covered with an upper flare diameter of 23 mm and a shaft 
diameter of 17 mm. In cases where the stent had to be located with its lower margin below the GEJ, non-
covered SEMS were often used to prevent migration. All stents were inserted by use of standard techniques 
with or without pre-dilatation of the stricture25. The insertion was performed as an in-patient procedure under 
conscious sedation or under general anesthesia.  
The endoluminal brachytherapy was performed using a high-dose-rate Iridium192 source (Figure 4). A 
10 mm applicator was used if possible, otherwise a 1.7 mm applicator carried the radiation source (only used 
in a minority of patients). The target was defined as the macroscopic tumor to which was added a 1 cm 
therapeutic margin in distal and proximal directions. The dose was prescribed at 10 mm depth from the 
surface of the applicator. Three fractions of 7 Gy were delivered with an interval of one to two weeks. 
In study V and VI, the surgery was performed as a joint venture between upper gastrointestinal-, ENT- 
and plastic reconstructive surgeons. In addition to lymphadenoidectomy, the larynx, hypopharynx and 
proximal esophagus were resected en-bloc with the intention to get a tumor free margin of ≥2 cm. A jejunal 
segment, 15-20 cm of length with a suitable long mesenteric pedicle was harvested via a midline abdominal 
incision and subsequently used as an interposition (Figure 5). The proximal end of the jejunal segment was 
closed by staplers and the pharyngo-jejunostomy was constructed either end-to-side or end-to-end by use of 
interrupted invaginated absorbable sutures. The distal jejuno-esophagostomy was sutured accordingly end-
to-end, again with absorbable suture material. Micro-vascular end-to-end and/or end-to-side anastomoses 
were performed to recipient vessels in the neck. The jejunal segment was harvested in combination with a 
shorter jejunal segment, 2-3 cm long. This segment, positioned outside the adjacent skin area in order to 
monitor viability of the transplant, was removed 3-6 days later. Approximately three months after initial 
surgery, a secondary tracheo-jejunal puncture using a speech valve (Provox I ) was established. 
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Figure 5. Jejunal interposition after pharyngo-laryngo-esophagectomy 
(PLE) (Paper V+VI). 
Comments 
The previously advocated non-expandable 
plastic prostheses have to a great extent been 
replaced by SEMS, mainly because of a 
better technical success rate, fewer com-
plications and lower mortality rates81. 
Consequently, the latter type was used in 
study I and II. Several types of SEMS exist 
on the market today, however, with slightly 
varying characteristics and clinical out-
comes26,82. In order to reduce an observed 
risk of migration, uncovered stents were 
previously recommended for cancers of the 
distal esophagus and the GEJ81. Today, 
covered stents are used throughout the entire 
esophagus, mainly because these recom-
mendations could not be supported by more 
recent studies and because the covering 
prevents ingrowth of tumor and granulation 
tissue into the stent27,83. Only a minority of the stents used in study I and II were uncovered, why a possible 
influence on outcome may be considered as unlikely. 
Reflux symptoms have been reported in up to 95% of patients where the stent has been placed across 
the GEJ84. Consequently, an anti-reflux valve has been established in some stent-types. These antireflux 
stents have shown good results concerning acid exposure in the lower esophagus as measured by 24h-pH 
monitoring85, however, the clinical benefit of antireflux stents for patients with cancer of the distal esophagus 
or the GEJ has yet to be confirmed78. Moreover, they were not commercially available at the time of study I 
and II, and hence not used. 
Low-dose rate brachytherapy schedules have today been replaced by the less time-consuming and more 
effective HDR concept86. The latter has been given as a single dose treatment or as fractionated sessions29. 
The fractionation allows a higher radiation dose and, according to some studies28, leads to better dysphagia 
and tumor control without a corresponding increase in side effects. Others have found an equally good relief 
of dysphagia after single session HDR brachytherapy and with an equal prevalence of side effects38,87. The 
brachytherapy given in study I and II were in accordance with recommendations by the American Brachy-
therapy Society88.  
Radical surgery including PLE and substitution with a free vascularized jejunal transplant in patients 
with cancer of the PEJ has been emphasized by many surgeons41,42,46 and is, since 1995, considered to be the 
first line of treatment at the Sahlgrenska University Hospital. The advantage of using a tubularized transplant 
for interposition, as opposed to myocutaneous flaps, is the reduced risk of strictures and fistula formation46. 
Moreover, this intervention is performed as a one-stage procedure. This reduces the peroperative time and 
shortens the hospital stay39. 
In study VI, pouches at the pharyngo-jejunostomy were found to induce a significant retardation of 
bolus transit in some patients. Despite the fact that this was not clearly related to clinical symptoms, it is 
reasonable to suggest that, if technically possible, the formation of such a pouch should be avoided. 
Jejunal graft 
Pharyngo-
jejunostomy 
Jejuno-
esophagostomy 
Tracheostomy 
Carotid 
artery 
Jugular vein 
Mesenteric 
pedicle 
Modifications of the pharyngo-jejunal anastomosis, e.g. to an end-to-end anastomosis, could therefore be of 
value. Such an approach was recently suggested by Okazaki et al., who also, in order to avoid strictures and 
fistula formation, used a “z-plasty-like” anastomosis- technique for the jejuno-esophagostomy in 20 patients 
undergoing PLE89. 
Clinical evaluations 
In study I and II, clinical evaluation was performed by a physician at the time of inclusion and 1, 3, 6, 9 and 
12 months later. The evaluation included recording of the Karnofsky Performance Status Scale Index 
(KPSSI)90 (Appendix 4), the grade of dysphagia according to Ogilvie et al.91, the patient’s weight and the 
occurrence of adverse events. In study IV, participating patients answered questions read by a physician from 
a standardized questionnaire on sociodemographic background, co-morbidity, weight loss and tumor-related 
symptom duration before diagnosis. The physician also registered the KPSSI and Body Mass Index (BMI). 
In study VI, ten survivors were evaluated with regard to their KPSSI, grade of dysphagia according to 
Ogilvie et al.91 and their Watson Dysphagia Score (WDS). In addition, the patients’ speech valve and/or 
electrolarynx (Servox) speech functions were assessed. 
Comments 
The KPSSI allows the physician to classify the patient according to the patient’s ability to perform normal 
activity, to do active work and the need for assistance rated on a scale from 0 to 100. It is established in 
clinical practice, is easy to estimate and can be used to compare the effectiveness of different therapies. 
Moreover, its interrater reliability and validity are considered to be good90.  
A scale for estimating the grade of dysphagia in patients with cancer of the esophagus or the GEJ was 
described by Ogilvie and co-workers in 198291. The scale has been used in many studies as well as in clinical 
practice, and describes the severity of the disorder. However, the grade of dysphagia is rated on a rather 
rough scale from 0 to 4 (0=no dysphagia; 1=some dysphagia, but no dietary limitations; 2=can drink, but 
only eat semisolid food; 3=can only drink; 4=total dysphagia) and has, to the best of our knowledge, not 
been validated in cancer patients. A more detailed description of the patient’s swallowing difficulties can be 
captured by estimating his or her WDS. This score was presented by Dakkak and co-workers in 1992 and 
ranges from 0 (no dysphagia) to 45 (severe dysphagia) on a 9-items scale (from liquids to solid food)92. The 
latter score has partly been validated in patients with various grades of esophageal strictures. 
Factors including gender, social functioning, a history of alcoholism and co-morbidity have previously 
been suggested to be related to psychiatric morbidity and were thereby a matter of interest in study IV67,69,75. 
Due to the limited number of patients and declining survival rates over time, imbalanced factors and small 
subgroups were, however, difficult to compare and evaluate. For some questions, there was also a certain 
risk of recall biases as suggested by the fact that none of the patients reported a previous history of an 
anxiety disorder or depression episode. The difficulty in obtaining a reliable estimate of a person’s alcohol 
consumption is also well-known. 
Several different methods of how to evaluate the voice quality after the establishment of a speech valve 
in patients surgically treated due to cancer of the PEJ have previously been described93,94. Most of them are, 
however, not validated and rather insensitive. A more advanced method, including spectrographic analysis of 
acoustic parameters, were described by Benazzo and co-workers in 200150. The speech valve assessments 
made in study V and VI were solely based on clinical grounds (mainly with regard to intelligibility, syllables 
per breath and degree of speech valve use), graded as good, average or poor and performed by a speech 
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pathologist and a surgeon in concordance. The main reasons for not doing a more sophisticated analysis was 
that the patients were relatively few in study V and the results generally poor in study VI. 
Evaluation with questionnaires 
All six studies comprising this thesis contained evaluation with questionnaires. In study I, III, V and VI, the 
EORTC QLQ-C30 (version 3.0) was used (Appendix 1). This questionnaire is tumor-specific and designed 
for self-administration. It has been used extensively in different HRQL-studies and it’s cross-cultural validity 
and psychometric properties are considered satisfactory32. The questionnaire comprises five functioning 
scales; physical-, role-, emotional-, cognitive- and social functioning. There are three symptom scales; 
fatigue, nausea/vomiting and pain and six single items relating to dyspnea, insomnia, loss of appetite, con-
stipation, diarrhea and financial difficulties. It also includes a global health status/QL scale (2 questions). A 
one-week time frame is employed. All scales and single-item scores are transformed into a score from 0 to 
100. A high score for a functional scale and for the global health status/QL scale represents a high/healthy 
level of functioning/high QL, while a high score for a symptom scale or single item represents a high level of 
symptoms/problems. The QL scores are calculated according to the EORTC QLQ-C30 scoring manual95. 
In study I, III and VI, the EORTC QLQ-OES18 was used (Appendix 2). This questionnaire consists of 
questions related to problems due to the specific tumor location and treatment33. The questionnaire comprises 
four scales: dysphagia-, eating-, reflux-, and local pain scale. There are 6 single items relating to problems 
with swallowing saliva, choking when swallowing, problems with dry mouth, problems with taste, problems 
with coughing, and problems with speech. Both the scales and single items are scored according to the same 
scoring system as the EORTC QLQ-C3095. Good psychometric and clinical validity for the questionnaire has 
been demonstrated in previous studies33. 
The HADS questionnaire was used in study I and IV (Appendix 3). It has been designed to screen for 
psychiatric morbidity in patients with somatic illness and comprises two scales, one for depression (seven 
questions) and one for anxiety (seven questions). Each item is rated on a four-point Likert scale. Cut-offs 
have been established for when to regard a patient as a probable (>10 points, on one scale) or possible (>7 
points, on one scale) case of psychiatric illness63. Scores indicating psychiatric morbidity (HADS total score) 
were defined as >7 points on either scale, i.e. a score indicating possible anxiety disorder and/or depression. 
The HADS questionnaire has been shown to perform well in assessing the symptom severity and caseness of 
anxiety disorders and depression in both somatic, psychiatric and primary care patients and in the general 
population96.  
Comments 
All of the above mentioned HRQL questionnaires has in common that they are filled in directly by the 
patient. The questions are answered on a multiple-choice scale (i.e. a Likert scale), and a certain time frame 
(i.e. one week) is employed. Matters of importance for a reliable interpretation of the HRQL data are that the 
compliance is high (i.e. the proportion of patients that answers the questionnaire) and that the amount of 
missing data is low (i.e. single questions that are not answered). It should be reasonably brief (i.e. preferably 
less than 10 minutes to complete) and easily understood. In addition, the occurrence of a response shift 
should always be kept in mind (i.e. the patient changes its perspective of his or her HRQL over time as a 
result of coping strategies, change in internal standards or increased knowledge). The latter phenomenon is, 
however, considered to be a natural adaptation to a disease and its treatment.  
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A disadvantage with written questionnaires is the inflexibility with regard to the response format and thereby 
the inability to further explore the responses. However, the questionnaires are easy to analyze, less time-
consuming than face-to-face interviews and reference data to the general population and other cancer popu-
lations exist78,97-100. Recent findings that certain questions of the HRQL questionnaires are more important 
than others101, and the subsequent development of shorter questionnaires102, further support this investi-
gational method as being suitable in patients with low performance status and rapid deterioration, e.g. 
patients with advanced cancer of the esophagus.  
For the HADS questionnaire, we used the cut-off levels for possible and probable affective disorder 
suggested by Zigmond and Snaith63. In a recently published overview, including 10 studies of cancer patients 
(n=1803), the mean optimal cut-off score for caseness on HADS-anxiety was 8.8 with a mean sensitivity of 
0.72 and a mean specificity of 0.8196. For HADS-depression, the mean cut off was 8.3 with a mean sensi-
tivity of 0.66 and specificity of 0.83. Moreover, the cut-off levels used here have previously been shown to 
have a high validity in Scandinavian patients with head and neck cancers67.  
Health economic evaluation 
In study II, internal hospital debits from the administration charts of 2003 at the Sahlgrenska University 
Hospital were used to assess the costs and the health economic view of the health care system was used. Cost 
assessment was started from the day of randomization and continued until death in order to estimate the total 
lifetime cost. The initial treatment cost was obtained by assessing all the costs from randomization until 
discharge from the hospital after cessation of treatment, i.e. after SEMS insertion or the last brachytherapy 
session. In addition, a health economic questionnaire was given to the patients at the various follow-up visits. 
In this questionnaire, patients were asked to report any contacts with the health care system since the last 
visit. However, to minimize the obvious risk of recall bias, a secondary data evaluation was performed by 
surveying the records in the hospital administration systems from the area where the patient lived. A sensi-
tivity (threshold) analysis was performed to assess the degree of difference in costs between the two 
comparators. 
Comments 
The “micro-costing” approach was not used, mainly because it was deemed to be work and time-consuming 
and the gap between costs of consumed resources and charges was considered to be small since the Swedish 
health care system is non-profitable. Cost-minimization analyses were carried out since there were no 
significant differences in outcome variables that could be used for a cost-effectiveness analysis. The costs 
were assessed from inclusion until death in order to capture the health economic effects, not only of the 
initial treatment, but also of re-intervention, late complications, hospice care etc. 
CT derived tumor size evaluation 
In study III, CT derived assessments of the tumors were performed on a diagnostic radiological workstation 
(CentricityTM RA600, GETM, Milwaukee, USA) and all measurements were performed on a high resolution 
screen (Coronis 3 MP, BarcoTM). The examinations were made at local hospitals with helical CT technique 
with a slice thickness of 5-10 mm. All measurements were done on series with intravenous contrast. If 
primary digital images were not available, previously printed images were digitalized using a scanner 
(Diagnostic Pro, VidarTM) with a resolution of 150 dpi. The length of the tumor was calculated as the number 
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of images in which the tumor could be localized multiplied by the 
slice thickness. To obtain the tumor volume, the cross sectional area 
was measured in each of these slices by manual outlining of the 
tumor on the screen using a mouse controlled cursor. In case of a 
visible lumen, this was also outlined and the luminal area was 
subtracted from the area calculated from the outer limit of the tumor 
(Figure 6). The cross sectional areas were multiplied by the slice 
thickness and the total volume calculated by the summation of these 
volumes (summation-of-area technique). The maximal tumor 
diameter was also measured.  
Comments Figure 6. Outlining of an esophageal tumor 
on a computerized tomography (CT) image  
(Paper III) 
Factors like slice thickness, image resolution, high quality multi-
planar reformation, the use of intravenous and/ or oral contrast 
media and antispasmodic drugs have been suggested to influence size assessment103,104. Great potentials thus 
exist for further refinement of this technique. Moreover, some reports state that more than 80% of volume 
measurement errors are due to the inter-observer variability105. All radiological measurements in study III 
were hence performed by one single consultant thoracic radiologist. Intra-observer variability in CT derived 
tumor size assessment has, on the other hand, been reported to be satisfactory106. The radiologist was, at time 
when the measurements were performed, unaware of the survival times of the patients. 
Barium examinations 
Figure 7. Barium examination showing the 
emptying of a jejunal graft with retention 
in a pouch (lateral projection) (Paper VI). 
The barium examinations in study VI were carried out in patients 
fasted for at least 6 hours. The study included both dynamic 
examination of motility with videofluoroscopy and a series of spot 
films, to evaluate morphology and emptying of the jejunal graft 
(Figure 7). The patients were asked to take 5 ml of barium (“High-
Density”, Astratech, Sweden) from a cup and then hold it in the 
mouth to test for adequacy of containment. They were then asked to 
swallow on command. Additional swallows of 15 ml “High-Density” 
contrast and of 5 ml of barium paste were recorded. Spot films of the 
jejunal interponate and the native esophagus were exposed, so that the 
localization of the anastomoses as well as any morphological abnor-
malities could be determined as accurately as possible. The transit of 
a bolus of 20 ml of barium through the jejunal segment and the remaining native esophagus was videotaped.  
The video recordings of swallowing were analyzed in slow motion and the findings recorded on a data 
sheet (Excel, Microsoft, Ca, USA) by two reviewers in consensus. Another data sheet was completed by a 
third, independent reviewer, to allow for calculation of inter-observer variability. Oral and/or pharyngeal 
dysfunction was graded as none, mild, moderate or severe. In addition to this qualitative assessment, a 
quantitative frame-by-frame analysis of the pharyngeal phase of the swallowing was performed. The func-
tion of the jejunal graft was assessed in relation to the degree of delay in bolus transit. The degree of intrinsic 
activity in the graft, as well as any localized delay or hold-up in transit of bolus, was also noted. The motility 
24 
in the remaining native esophagus was evaluated with regard to the presence of non-propulsive, tertiary 
contractions, delayed esophageal emptying and impaired LES relaxation.  
Comments 
The value of radiographic evaluation, as opposed to techniques such as scintigraphy, lies in a better ability to 
differentiate between structural and functional disturbances107. This is of importance when assessing patients 
with esophageal cancer, especially after substitution with a jejunal graft where endoscopic surveillance may 
be associated with difficulties. Moreover, although experienced radiologists were involved, a radiological 
assessment is a subjective thing with observer variability. Consequently, in study VI, effort was put on 
estimating the degree of inter-observer variability regarding the radiological evaluations. 
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Statistics and ethics 
The majority of the statistical analyses in this thesis were performed by Statistiska Konsultgruppen, 
Göteborg. All 6 studies were approved by the local ethics committees and informed consent was obtained 
from each participating patient before inclusion. 
Paper I and II 
A sample size of 75 patients in each treatment arm was calculated from 30% difference in dysphagia score 
with a power of 80% at a 0.05 significance level. An interim analysis was planned after 60 enrolled patients. 
After this analysis, the inclusion was stopped since significant differences between the groups were 
observed. The presented data refers to a PP-analysis in Paper I and an ITT-analysis in Paper II. In Paper I, for 
comparison between groups, Fisher’s non-parametric permutation test108 was used for continuous variables, 
Mantel-Haenszel’s Chi-square test for ordered categorical variables and Fisher’s exact test for dichotomous 
variables. For comparison over time within groups, Fisher’s non-parametric permutation test for matched 
pairs108 was conducted. A difference of 10 points in the QoL scores was regarded as clinically relevant109,110. 
In Paper II, Mann-Whitney test was used for numerical variables and chi-square and Fischer’s exact test for 
comparisons for categorical variables as appropriate between groups. Survival analysis was performed with 
Kaplan-Meier estimates and formally tested with Log-Rank-test. All tests were two-tailed and conducted at a 
5% significance level. Data were expressed as means and SD if not stated otherwise.  
Paper III 
For descriptive purposes, frequencies and percent were computed for categorical and dichotomous variables 
and mean, SD, median and range for continuous variables. Mann-Whitney U-test was used for test between 
two groups with respect to continuous variables. The effect of a predictor on time to death was described 
with Hazard Ratio. The survival analysis was performed by using Cox Proportional Hazard Model. For 
survival analysis of dichotomous and non-ordered categorical variables as predictors, the Log-rank test was 
used. For description of survival analyses, Kaplan-Meier graphs were used. To control for possible con-
founding effects of established prognostic factors and associations between CT derived size assessment of 
the primary tumor as well as HRQL scores, multivariable models using a stepwise Cox regression procedure 
were performed. Variables that were not significant on a 5% level in the univariate analysis, that were too 
unevenly balanced, had a high percentage of missing data or showed a high correlation with other potential 
prognostic variables were not included into the multivariate procedure. Univariate and multiple stepwise 
logistic regression were used to select independent predictors for probability of death before and after 3 
months. Bootstrapping techniques were used for internal validation of the multivariate model. Bootstrap 
samples were drawn with replacement and with the same size as the original sample. Cox Proportional 
Hazard model was created within each bootstrap sample and best sets of independent variables were defined. 
This procedure was repeated 1000 times to obtain stable estimates of the optimism of the model, i.e. how 
much the model performance was expected to decrease in new patients. All tests were two-tailed and 
conducted at a 5% significance level. To control for multiple significance, the upper limit of the expected 
number of false significances was calculated. The upper limit of expected number is calculated by alpha * 
(N-n (alpha)) / (1-alpha), where N = number of tests, n (alpha) = number of significances on level alpha and 
alpha = significance level.  
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Paper IV 
For descriptive purposes, frequencies and percent were computed. Between group comparisons were 
performed using the Pitman’s nonparametric permutation test for all correlation analyses108, along with 
Pearson’s correlation coefficient for descriptive purposes. Fisher’s non-parametric permutation test was used 
when comparing ordered and continuous variables between groups108. Change over time was tested for 
ordered categorical variables (HADS scores) using the sign test. Mantel-Haenszel’s Chi-square test was used 
for measuring changes between groups. For survival analyses, the Log-rank-test was used for binomial or 
non-ordered categorical variables and Cox’s PH-regression was used for ordered or continuous variables. All 
tests were two-tailed and conducted at a 5 % significance level. 
Paper V and VI 
Inter-observer agreement of the radiological findings was assessed by calculation of the weighted kappa-
value111. 
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Results and comments 
Paper I and II 
Out of the 65 patients randomized, 28 patients completed the SEMS 
treatment and 24 patients the brachytherapy and were hence eligible for 
the PP-analysis in study I. 5 patients chose to withdraw their consent 
after randomization and consequently, 60 patients (30 patients in each 
arm) were eligible for the ITT-analysis in study II. Six patients died 
before having or completing the stipulated treatment and 2 were 
excluded due to technical difficulties (both patients being allocated to 
brachytherapy) (Figure 8). Mean time from inclusion until start of 
treatment was 10.9 days for the SEMS group and 17.3 days for the 
brachytherapy group. 
Compliance for the HRQL questionnaires was adequate (>80%)  
at all measurement-points and missing data were few (2%). Mean 
global QL scores at inclusion were 43 for the SEMS group and 44 for 
the brachytherapy group. The group of patients treated with SEMS 
reported significantly better HRQL scores for dysphagia at the one-
month follow-up than at inclusion, but most other HRQL scores, 
including functioning and symptom scales, deteriorated over time. 
Among brachytherapy-treated patients, improvements were found for 
the dysphagia-related scores at the three-month follow-up, whereas 
other significant changes of HRQL scores over time were few and 
hence more stable than in the SEMS group. Psychiatric morbidity, as 
assessed by the HADS questionnaire, was common (>60% of patients 
at inclusion) with no preponderance to either treatment strategy.  
Figure 8. Number of randomized 
patients, withdrawals before start of 
treatment, number of patients available 
for the intention-to-treat (ITT) analysis 
and number of patients completing the 
treatment (available for the per-protocol 
(PP) analysis), for the two treatment 
groups (Paper I+II). 
A statistically significant improvement in the dysphagia score according to Ogilvie et al.91 was reported 
for the SEMS group at the 1-month follow-up (Figure 9). This difference was, however, not seen at the 
subsequent follow-up at 3-months. No significant differences for 
KPSSI, weight loss or the occurrence of adverse events were found 
between the two groups and the survival times were comparable 
(median survival time around 120 days) (Figure 10).  
The median total lifetime cost and initial treatment cost for 
brachytherapy were significantly higher compared to those for SEMS 
treatment (€33171 vs. €17690 and €23857 vs. €4615, respectively). 
This difference was mainly due to higher costs for the therapeutic 
procedure and for in-hospital stay (Table 3). Sensitivity analyses 
showed that the charge for a brachytherapy session had to be reduced 
from €6092 to €4222 to make this therapeutic concept cost-competi-
tive. Consequently, stenting was found to be more cost-effective 
compared to brachytherapy. 
Figure 9. Significant (p=0.03) change in 
dysphagia scores between inclusion and 
the 1 month follow-up in favour of the 
stented patients (Paper II). 
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Comments 
Figure 10. Cumulative survival rate from inclusion 
plotted as Kaplan-Meier estimates (Paper II). 
HRQL proved to be generally poor in patients evaluated, 
both at inclusion and over time. Global QL-scores were 
considerably lower than in the general population100 and 
also compared to other cancer populations97,98,112. In 
addition, the survival time was very limited in both 
groups, emphasizing the obvious need for a rapid effect of 
treatment. The immediate mechanical effect of the SEMS 
offered a more prompt effect on dysphagia than frac-
tionated HDR brachytherapy. In addition, time from 
inclusion until start and end of initial treatment varied 
between the two comparators and was in favor of the 
SEMS treatment. Consequently, these patients reported 
improved dysphagia scores at the one-month follow-up. A reduced delay from inclusion until the start of 
brachytherapy, possibly given as a single session with a higher dose87, could level out some of this dis-
crepancy. However, others report a similar outcome as in our study with the latter brachytherapy schedule38.  
An overall improvement of dysphagia was only found in 40% of the patients regardless of treatment, 
inferior to that reported by others26,38,87. An explanation for this could be that the scoring of dysphagia in our 
study was done by a physician, in contrast to others that have used diary cards38. Another possible way to 
better investigate the effect on dysphagia would have been to measure HRQL including the dysphagia scale 
of the EORTC QLQ OES18 at tighter intervals during the first months, but this could severely have 
hampered the compliance in these vulnerable patients. 
The fact that HRQL showed a less pronounced deterioration over time in the brachytherapy group is 
somewhat surprising in view of the more prompt effect on dysphagia with SEMS treatment. This finding, 
which has also been confirmed by others38, may in part be explained by initially more frequent contacts with 
the health care system in the brachytherapy group. Another field, that is open for speculations, is to what 
extent the psychological effects of a treatment directed towards the uncontrolled neoplastic growth could 
contribute to a better outcome. Nevertheless, the results indicate that SEMS is the more favorable modality 
in patients with a short expected survival (< 3 months), while brachytherapy might be preferable in patients 
with a longer ditto.  
Table 3. Total lifetime costs divided into used resources (Paper II).
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Health economic analyses must include both costs and outcome measurements to be meaningful76. While 
differences between other endpoints were comparatively modest, our study showed an overwhelming 
difference between costs for SEMS and brachytherapy in favor of the former treatment. Consequently, 
stenting was found to be the most cost-effective concept. One should, however, bear in mind that this 
conclusion is only valid in the present setting, i.e. a Swedish non-profitable health care system with the 
majority of the initial treatments being performed under general anesthesia and with 3 sessions of 
brachytherapy. In fact, in a Dutch study using a “micro-costing” approach, Homs et al. found a health 
economic outcome that was comparable between SEMS and brachytherapy when the latter treatment was 
given as a single session of 12 Gy and both SEMS and brachytherapy were performed under sedation as an 
out-patient procedure38.   
Paper III 
In the univariate analysis, KPSSI, M-stage and 
UICC-stage were found to be significantly related 
to survival (Table 4). A larger CT-derived tumor 
volume, as well as a wider maximal diameter, was 
found to be associated with a shorter survival time. 
In addition, 10 of the 25 scales and single items of 
the EORTC QLQ-C30 and QLQ-OES18 were also 
found to predict survival.  
Table 4. Univariate Cox analysis (Paper III). 
Variable Hazard Ratio* (95% CI) p Value 
KPSSI 0.98(0.96-0.99) 0.002 
M-stage 1.89 (1.21-2.91) 0.004 
UICC-stage 1.44 (1.05-1.96) 0.03 
CT-volume pr. tum. (cm3) 1.005(1.001-1.009) 0.025 
CT-max diameter pr. tum. (cm) 1.026(1.009-1.043) 0.002 
EORTC QLQ-C30: 
 
 
   Physical function 0.91(0.85-0.99) 0.02 
   Role function 0.92(0.86-0.97) 0.004 
   Cognitive function 0.92(0.86-0.99) 0.03 
   Fatigue 1.12(1.05-1.21) 0.001 
   Pain 1.10(1.03-1.17) 0.006 
   Dyspnea 1.08(1.02-1.14) 0.014 
   Appetite loss 1.07(1.01-1.13) 0.016 
EORTC QLQ-OES18: 
  
   Eating scale 1.10(1.01-1.19) 0.031 
   Reflux scale 1.15(1.05-1.25) 0.002 
   Trouble with speech 1.08(1.00-1.16) 0.038 
*Hazard ratio for HRQL scores provides the likelihood of death at any given time for a  
patient with a score of 10 points more than another patient; KPSSI=Karnofsky Per- 
formance Status Scale Index; UICC=Union Internationale Contre le Cancer; pr. tum.= 
primary tumor 
Factors significantly correlated to survival 
were also tested in a Cox multivariate model. The 
fatigue scale from the EORTC QLQ C-30 
questionnaire, as well as the reflux scale from the 
esophageal module, were found to add prognostic 
information to the strongest predictor, i.e. M-stage, 
and were thus independent predictors of survival 
(Table 5). A higher score of 10 points for a patient 
was found to increase the likelihood of death, at 
any given time, with 10% for the fatigue scale and 
with 11% for the reflux scale. In patients without metastases (M0-stage), the reflux scale was found to be the 
strongest independent predictor of survival, with a 33% higher likelihood of death, at any given time, for a 
patient that scored 10 points more than another patient. The physical functioning scale was found to be the 
strongest independent predictor in patients with metastatic disease (M1-stage), with a corresponding figure 
of 16%. 
A subgroup analysis of the single questions comprising the scales was also performed. Question no 4 
(“Do you need to stay in bed or a chair during the day?”) in the physical functioning scale and question no 12 
(“Have you felt weak?”) in the fatigue scale of the EORTC QLQ-C30 questionnaire, as well as question no 
44 (“Have you had acid indigestion or heartburn?”) in the reflux scale of the EORTC QLQ-OES18 
questionnaire were found to be the most important questions for prediction of survival.  
To confirm the established prognostic model, a risk group validation was performed by dividing the 
patients into two groups. The groups consisted of those who died prior to 3 month after inclusion (n=47) vs. 
those who lived longer (n=49). A logistic regression analysis was then performed to evaluate potential 
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predictive factors. M-stage was again found to be the strongest predictor of survival, followed by fatigue, 
physical functioning and the reflux scale. A bootstrapping re-sampling analysis further confirmed the 
replication stability of the final model. 
Comments 
Traditionally, much focus has been on the definition and evaluation of prognostic factors for patients with 
tumor states enabling therapy for cure113. In Study III, we shifted this focus to the larger group, i.e. those 
where palliative treatment is the only option. The issue of how to best palliate patients with advanced cancer 
of the esophagus and GEJ is pivotal since the clinician has to choose between therapeutic options with a 
range of pros and cons. Study III consequently offers guidelines for the selection of patients for stenting and 
others in who more advanced palliative therapeutic modalities, e.g. brachytherapy, shall be considered.  
While the found predictors of survival showed a high level of reliability, it must be remembered that the 
analyses were performed on data from patients included in two different randomized trials. Even though the 
inclusion and exclusion criteria were mainly the same for the two trials, fusion of data could result in biases. 
As a consequence, the final model was tested on subgroups with patients included in one trial only, as well as 
in patients treated with either SEMS or brachytherapy, with an outcome that confirmed its reliability. In spite 
of this, care should be taken when interpreting the results and before applying them in clinical practice.  
The findings that M-stage, as well as the EORTC QLQ-C30 physical functioning and the fatigue scale, 
are predictors of survival in cancer patients have been confirmed in several other studies34,35,114,115. An 
unexpected finding was, however, that the reflux scale also turned out to be an independent predictor of 
survival, not only in patients without metastases, but for the whole study-group. Why the degree of acid 
indigestion or heartburn would be related to the patient’s remaining life-span is not easy to understand, but 
this symptom appears to be related to a more aggressive type of tumor or disease state.  
Table 5. Final Cox multivariate models (Paper III). 
Variable Hazard Ratio* (95% CI) p Value 
Whole study group (n=96)   
   M-stage 2.15 (1.35-3.43) 0.0013 
   Fatigue 1.10 (1.02-1.19) 0.016 
   Reflux scale 1.11 (1.00-1.22) 0.040 
Patients with M0-stage (n=36)   
   Reflux scale 1.33 (1.11-1.61) 0.0026 
Patients with M1-stage (n=52)   
   Physical functioning 0.84 (0.75-0.93) 0.0012 
*Hazard ratio for HRQL scores provides the likelihood of death at any given time for a  
patient with a score of 10 points more than another patient. 
Although a relation to survival for two of the CT derived tumor size parameters could be confirmed, 
they could not be established as independent predictors. However, it is important to remember that, for 
various reasons, size assessment could be performed in only 58% of the patients. In 20 patients, a CT had not 
been performed at all or was not performed 
within a reasonable time-frame. The CT 
examination had been destroyed in 12 patients, 
and in 8 patients, with distally located tumors, 
the tumor margins could not clearly be delineated 
from ordinary gastric tissue. One criterion for 
excluding a variable in a multivariate analysis is 
a high amount of missing data. Hence, the 
question whether CT derived tumor size para-
meters are independent predictors of survival in 
patients with incurable cancer of the esophagus 
or not remains unanswered.   
Paper IV 
At inclusion, 42% of the 90 patients evaluated had HADS-scores indicating psychiatric morbidity (i.e. either 
probable or possible anxiety disorder and/or depression) (Figure 11). No statistically significant change in 
the HADS total score over time was found; neither for any sociodemographic subgroup, nor for any clinical 
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subgroup. However, the majority (73%) of patients with scores indicating depression at inclusion also 
reported scores indicating anxiety disorder, demonstrating a high degree of co-variation for the two disease 
states evaluated. This trend was seen in patients treated both with curative and palliative intent and was 
maintained over time.  
During the study year, the proportion of patients with scores indicating possible/probable anxiety 
disorder (>7 points on the anxiety scale) ranged between 16% and 34% and was highest at inclusion. At all 
follow-ups, except at 3 months, this proportion was significantly lower than at inclusion. After an initial 
decrease in both treatment groups, anxiety score levels similar to those reported at inclusion was again found 
at the 3 month follow-up for those treated with curative intent. A positive correlation was found between 
HADS anxiety scores at inclusion and the duration of tumor-related symptoms prediagnosis. Moreover, a 
larger proportion of patients with a duration of tumor-related symptoms prediagnosis exceeding 6 months 
scored worse than the other patients on anxiety at the 1- and 6-month follow-ups. Compared to male patients, 
a significantly larger proportion of female patients had possible/ probable anxiety disorder at the 1-, 2- and 3 
month follow-ups. No other significant change over time in HADS anxiety scores was found; neither for the 
whole study group, nor for any subgroup. 
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Figure 11. Percentage of all patients that completed the questionnaire with scores 
indicating possible (>7-10 points) or probable (>10 points) anxiety (a), depression (d) 
anxiety and/or depression (t). Incl=inclusion; mo=month (Paper IV). 
Regarding depression, the proportion of patients with HADS scores >7 points ranged between 27% and 
44% during the study year, with a tendency (ns) to increase over the first 6 months. A significantly larger 
proportion of patients with scores indicating depression was found at inclusion among patients treated with 
palliative intent compared to those treated with curative intent. A negative correlation was also found 
between depression scores and KPSSI scores at inclusion. Moreover, a tendency was found towards a lower 
proportion of patients with 
depression scores >7 points 
among survivors compared to 
patients who died. No other 
statistically significant 
differences were found between 
the two treatment groups over 
time, nor for the sociodemo-
graphic subgroups or the other 
clinical subgroups analyzed. No 
correlations between HADS 
scores and survival were found. 
Comments 
About 25-30% of all cancer patients are reported to develop clinically significant anxiety disorder and 
depression within 2 years of diagnosis67. The present study showed that a large proportion of patients with 
newly diagnosed esophageal cancer suffer from symptoms of anxiety and/or depression as measured by the 
HADS questionnaire. In addition, the present findings are in line with previous reports from studies of cancer 
with a poor prognosis116,117. 
The occurrence of anxiety at inclusion was significantly related to the duration of symptoms pre-
diagnosis. An explanation for this could be that patients with a pre-morbid anxiety disorder tend to suppress 
their symptoms more than do others and thus seek medical care at a later stage. In contrast to these results, 
and to some previous observations among head and neck cancer patients71, we did not find a relationship 
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between anxiety and TNM-stage, KPSSI score or treatment regime. Our findings also contrast with results 
that females score worse than males on the anxiety scale at diagnosis67,74. On the other hand, our female 
patients scored worse at the 1-, 2- and 3-month follow-ups, but the proportion of females was fairly low. 
In contrast to what has been reported for instance regarding lung cancer patients118, we could not verify 
that lower social functioning, e.g. living alone, and more physical symptoms or co-morbidity predict 
depression, although many of our patients had a relatively advanced tumor burden with a low survival rate, 
and at least 9 patients suffered from excessive alcohol consumption. However, depression was less common 
among patients who were eligible for treatment with curative intent, a group which in this study contained 
less subjects living alone and with a lower degree of co-morbidity compared to those who received palliative 
treatment.  
A time pattern, similar to that reported by Shepherd et al. 70, with highest anxiety scores at diagnosis 
and highest depression scores during treatment, was observed. A possible explanation could be that as the 
patients gradually become more aware of the implications of their diagnosis and prognosis, the more 
depressed they get. The dampening effect on anxiety over-time, on the other hand, could be associated with 
the care and treatment the patients receive. It is also possible that the information given regarding the 
expected outcome may have an impact, as suggested by the fact that patients who received treatment with 
palliative intent scored worse for depression compared to those who survived the whole study period, as well 
as by the observation that those in the “curative group” who died scored relatively low on the depression 
scale. However, the results must be interpreted bearing in mind that this study had a strictly descriptive 
purpose and that factors not accounted for in the study might be involved, such as post-operative morbidity, 
change in medication but also the decreasing patient sample size due to mortality, especially for patients that 
received palliative treatment. Compliance, which was very high in contrast to previous reports of patients 
with a relatively advanced disease118, was, on the other hand, less likely to be a factor of importance.  
Paper V and VI 
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Figure 12. Cumulative survival rate from the time of initial 
surgery plotted as Kaplan Meier estimates for the 16 patients 
who have undergone pharyngo-laryngo-esophagectomy at 
the Sahlgrenska University Hospital since 1995 (Paper VI).  
Between June 1995 and October 2005, three patients 
with hypopharyngeal cancer and 13 consecutive patients 
with proximal esophageal cancer (15 males and 1 
female) underwent circumferential PLE to which was 
added a free vascularized jejunal transplant (n=14), 
colonic transposition (n=1) or a gastric tube (n=1) at the 
Sahlgrenska University Hospital. All patients underwent 
surgery with curative intent. The patients with hypo-
pharyngeal cancer received initial treatment with full-
dose radiotherapy (64 Gy), but due to remaining tumor 
growth, they were offered rescue surgery. Patients with 
a tumor site in the proximal esophagus were treated 
with preoperative chemoradiotherapy (cisplatinum,  
5-FU and 40.8 Gy), except for one patient that 7 years 
prior to the operation had received radiotherapy (58 
Gy) due to a laryngeal carcinoma. All operations had a per- and postoperative uneventful course and post-
operative examination in study V showed histopathological down-staging in all cases. The duration of the 
operations presented in study V ranged between 7h 20 min and 13h. By the time of the follow-up in study 
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VI, four of the 16 patients had died due to metastatic disease and two patients had died due to myocardial 
infarction (Figure 12). In addition, two patients were recently diagnosed with local recurrence. 
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At the various follow-ups, KPSSI ranged from 70-90 (Paper V) and 60-90 (Paper VI), respectively. For 
the 10 survivors evaluated in Paper VI (mean follow-up time 54 months), Global QoL was generally good 
(mean 74), and the degree of dysphagia according to Ogilvie et al., the mean WDS (Figure 13) and the 
dysphagia related scales and items of the EORTC QLQ OES-18 indicated a comparatively good ability to 
swallow. In spite of this, radiographical signs of disturbed bolus transport through the jejunal transplant and 
the remaining native esophagus were found in all patients examined. No correlation was, however, found 
between radiographic findings and clinical assess-
ment or outcome from the HRQL questionnaire. 
The inter-observer agreement concerning the 
various radiological findings was high (weighted 
kappa = 0.81).  
The speech valve function was initially 
assessed as good in one patient, average in two 
patients and poor in one patient (Paper V). At the 
later follow-up (Paper VI), all patients with a 
speech valve were considered to have a poor 
function. All patients learned how to use Servox 
speech, however, and could thereby maintain an 
acceptable way of communication. 
Figure 13. Watson Dysphagia Scores (WDS) for the 10 
survivors that underwent pharyngo-laryngo-esophagectomy 
(PLE) (Paper VI). 
Comments 
Only a few reports exist describing the outcome after neoadjuvant chemoradiotherapy followed by PLE 
including substitution with a free jejunal transplant and the subsequent establishment of a speech valve. 
Hence, study V and VI substantially contributes to the knowledge within this field and, in addition, present 
an exceptional long-term follow-up. Our results, including no cases of peroperative deaths, no cases of graft 
necrosis, down-staging after chemoradiotherapy in all cases examined, an acceptable morbidity and a 
promising outcome in terms of survival, gives further support to the feasibility of this strategy and to its 
maintenance in the therapeutic arsenal.  
Most patients examined in study VI demonstrated adequate oro-pharyngeal swallowing, despite radio-
logical signs of disturbed bolus passage through the jejunal graft. Based on the clinical assessments and the 
results from the HRQL questionnaires, dysphagia was, however, relatively mild in those patients who were 
free of tumor recurrence, with a high rate of full oral nutrition in accord with previously reported 
series41,45,46,50. This discrepancy undoubtedly suggests a variety of different reasons behind dysphagia in 
these patients. Furthermore, the mean global health status/QoL score was 74, which compares well to the 
general Swedish population100.  
The mean Watson Dysphagia Score was in the vicinity of that seen in patients surgically treated for 
achalasia119, whereas the EORTC QLQ OES-18 based dysphagia scale was close to that reported by Viklund 
et al. in patients surgically treated due to cancer of the intrathoracic esophagus or GEJ99. Whether this is due 
to a lack of perception in a denervated tissue is open for speculation, but a poor correlation between 
symptoms of dysphagia and motility patterns has previously been reported also in non-operated patients 
examined by manometry120. It must also be remembered that the pre-surgical expectations on the swallowing 
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ability after the operation might have influenced the self-assessed scoring, contributing to a response shift in 
the HRQL parameters. Thus, low expectations may have contributed to a relatively good score in a patient 
with a jejunal transplant, while an otherwise healthy person would have scored the same swallowing 
difficulties as more severe.  
In contrast, the assessment of patients’ speech valve functions revealed rather discouraging results. 
After some hopeful outcomes, at least initially, following intense training lead by a speech pathologist (Paper 
V), the apprehension at the later follow-up (Paper VI) was that the speech valve functions in our patients 
were generally poor. One of the main reasons for this poor outcome was frequent problems with leakage and 
thereby an inability to produce intelligible speech. As opposed to the native esophageal wall, the jejunal graft 
is comparatively sensitive why an erosive effect of the collars of the speech valve easily occurs. Broader 
collars that reduce the pressure on the jejunal wall could possibly be a feasible solution to this problem.    
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General discussion and future perspectives 
For a disease associated with such a dismal prognosis as cancer of the esophagus, several aspects exist 
regarding the management of the patients concerned. The aim of this thesis is to put focus on some of those. 
Comprising the majority of patients, the centre of attention has to a great extent been those with an incurable 
disease destined for palliative care. Questions related to morbidity, adverse events, quality of life, mental 
illness and health economy have been emphasized; factors of special importance when handling patients with 
a limited life-span. However, cancer of the esophagus constitutes a wide specter of different disease states, 
including various tumor-stages, localizations, subtypes and the eligibility for curative treatment or not. 
Hence, the perspective on the management of these patients can be immensely widened. 
Esophageal cancer remains a significant public health problem worldwide and prevention is of utmost 
importance. The vast majority of cases of squamous cell carcinoma can be explained by the use and abuse of 
tobacco products and alcohol, but a diet lacking in fresh fruits and vegetables may also play a role121. 
Another field of recent interest is the role of HPV infections in squamous cell carcinoma and the suggested 
benefit of vaccination schedules15. Thus, there is no shortage of potential targets for primary prevention 
efforts. For adenocarcinoma, on the other hand, the conditions are more ambiguous. Even though some risk 
factors are known, the benefit of strategies such as weight reduction, treatment of GERD or long-term 
surveillance of Barrett’s esophagus have not yet been clearly established121. Nevertheless, chemoprevention 
has recently been suggested for patients at risk122. A daily intake of a non-steroidal anti-inflammatory drug, 
e.g. aspirin, may have a risk-reducing effect in some patients123. 
Although slightly improved survival rates have been observed in some countries during the last 
decade24, the overall outcome in patients with esophageal cancer, even after treatment with a curative intent, 
is still disappointing. While there is still room for improvements of surgical procedures and radiation 
schedules, major steps towards better results will probably appear within the field of chemotherapy and 
targeted agents. Several classes of novel targets for the latter approach has been described, which include 
interference with growth regulatory signals, inhibition of angiogenesis, interference with uncontrolled 
replication, promotion of apoptosis and inhibition of invasion, metastasis and inflammation124. 
Today, the two most viable strategies for relief of dysphagia in patients with incurable cancer of the 
esophagus are SEMS treatment or brachytherapy. We, and others38,114, have showed that both concepts have 
a place on the therapeutic arena and that careful selection of candidates are important to obtain a satisfactory 
outcome. Predictors of survival could be a help in this selection. An interventional study, performed in a new 
set of patients, which utilizes the found predictors in the choice of therapy could be a way to verify the 
generalizability and usefulness of our findings. Another approach, recently undertaken by our team, would 
be to combine the advantages of the two comparators. Consequently, this concept consists of SEMS insertion 
followed by immediate brachytherapy given as a single session. When testing such a novel strategy, careful 
monitoring of the occurrence of adverse events is of course an important aspect. 
Other fields of interest, when considering strategies for relief of dysphagia and palliation in patients 
with esophageal cancer, are the development of new types of stents and new combinations of cytotoxic 
drugs. The enhancement within stent-designing, including development of biogradable stents, stents with a 
radioactive coating as well as cytotoxic drug-eluting stents, is one promising route to achieve progress7. The 
combination of epirubicin, cisplatinum and 5-FU (ECF) was recently found to offer better HRQL after 3 and 
6 months compared to another scheme of chemotherapy in patients with advanced esophagogastric cancer, 
and could hence be an alternative for patients with a longer remaining life-expectancy125.    
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The findings of a correlation between CT derived size assessment of the primary tumor and survival in study 
III is interesting, especially since no correlation between T-stage and survival was found. Although not 
confirmed in our study, the actual volume, length or diameter of the primary tumor could prove to be a better 
prognostic factor than the level of invasion into the esophageal wall as traditionally assessed by EUS20. The 
CT scans in our study consisted of axial images only, but the use of thin collimation, that allows high quality 
multiplanar reformation, would significantly improve the three-dimensional measurements. The use of 
positive or negative oral contrast media just before the CT examination, with or without antispasmodic drugs 
(e.g. N-butylscopolamine) to distend the esophagus and stomach103, would allow a better delineate of the 
limits of tumors. The use of MRI may also be a feasible alternative since it may be superior to CT in tumor 
size evaluation due to better multiplanar imaging and better contrast between soft-tissues104. Consequently, 
this topic needs further investigation. As the technical development advances, numerous interesting findings 
and applications could be expected within this field. 
Since the life time risk for a person to have an anxiety disorder or depression is reasonably high65,66, as 
well as the fact that several studies report an increased prevalence of psychiatric morbidity within cancer 
populations67,71-73, screening for these disease states are of great importance to offer adequate treatment and 
enhance compliance. Although none of the patients in study IV reported a previous or on-going episode of 
anxiety disorder or depression at inclusion, there was an obvious risk of recall biases when collecting these 
data. In addition, many psychiatric diseases are under-diagnosed and not always obvious to the patient66. A 
more active interview at inclusion, with questions especially focusing on these aspects, could possibly have 
resulted in more reliable information at baseline.  
The feasibility of the HADS questionnaire as a valid and reliable tool for detection of a possible or 
probable anxiety disorder and/or depression has been confirmed by many67-69,96. However, most studies done 
so far, including our own, have all aimed to screen for illness and describe the prevalence within a certain 
population. Only a few studies have incorporated interventional procedures and thereby given guidelines for 
using the questionnaire as an instrument in clinical practice. An example of the latter kind of study was 
recently performed in breast cancer patients with results that further support the usefulness of the HADS 
questionnaire126. Accordingly, the next step for researchers that share our field of interest would be to set up 
similar studies in patients with esophageal cancer. 
Radical surgery for cancer of the PEJ involves huge resources in terms of adequate preoperative 
investigations, time in the operating theatre, collaboration between different professions, accurate monitoring 
of the patients per- and postoperatively and preparedness in the case of urgent complications. Consequently, 
PLE is mainly performed in high-volume centers. The relative scarcity of candidates suitable for this kind of 
intervention, as well as the constant need for maintenance of surgical skills, give further support to this 
centralization127. Nevertheless, there is always room for improvements. 
Several studies report inferior results for speech valve function among patients operated with a free 
jejunal transplant reconstruction due to cancer of the PEJ compared to patients with laryngeal cancer that has 
undergone laryngectomy alone93,94. It has been proposed that the reason for this might be the intrinsic 
motility, the lack of muscle layers of the transplant or the absence of the pharyngo-esophageal segment50,94. 
The function of the speech valves assessed in study VI was indeed rated as generally poor, and HRQL scores 
for trouble with speech reached a mean value of 47. Some studies have reported a better outcome48,50,93, 
while others have suggested preservation of the larynx even with the use of free jejunal transplant 
reconstruction43,128. The obvious reasons for this would be maintenance of the patient’s own voice and, as a 
consequence, a better quality of life. However, there are two obvious risks associated to this surgical 
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strategy; one is to offer incomplete radicality. Secondly, the present findings of frequent oro-pharyngeal 
regurgitations suggest that larynx-sparing surgery may as well be burdened by aspirations to the respiratory 
tract as has frequently been observed in patients operated with gastric pull up129. 
The task to find the optimal curative treatment for patients with cancer of the PEJ remains. While many 
centers recommend a similar concept as described in Paper V and VI41-43, others propose a more conservative 
strategy with chemoradiotherapy alone52,130,131. The pros and cons in terms of the chances to relieve dys-
phagia, maintain an acceptable voice quality, reduce the risk for complications and, most importantly, to 
maximize the chances for survival must carefully be considered before choice upon therapy. However, today 
the lack of prospective studies gives the decision-maker little guidance. To conduct a randomized controlled 
trial, comparing neoadjuvant chemoradiotherapy followed by PLE with chemoradiotherapy alone, would be 
the next important step to gain more knowledge within this field and would, furthermore, be ethically 
motivated.  
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General conclusion 
• Patients with incurable cancer of the esophagus or the GEJ have a severely deteriorated HRQL, both 
at inclusion and over time.  
 
• Insertion of a self-expandable metal stent offers a more instant relief of dysphagia compared to 
endoluminal brachytherapy. In addition, stent treatment is currently more cost-effective than 
fractionated brachytherapy. 
 
• Deterioration of HRQL was less pronounced in patients that receive brachytherapy, and after 3 
months, relief of dysphagia was equal for the two comparators. Consequently, brachytherapy is a 
viable alternative in patients with a longer remaining life-expectancy. 
 
• KPSSI, M-stage, UICC-stage, CT-derived tumor size parameters and 10 of the 25 scales and single 
items of the EORTC QLQ-C30 and QLQ-OES18 questionnaires correlate to survival in patients with 
incurable cancer of the esophagus or the GEJ. 
 
• The physical functioning, fatigue and reflux scales are independent predictors of survival in patients 
with incurable cancer of the esophagus or the GEJ, while M-stage is the strongest predictor. 
 
• Psychiatric morbidity is common among esophageal cancer patients, both at inclusion and over time 
regardless of the cancer-therapy given.  
 
• Reconstruction after radical resection for cancer of the PEJ can be carried out with low peroperative 
mortality, acceptable morbidity and a promising functional outcome. 
 
• HRQL was generally good after surgical treatment due to cancer of the PEJ, with mild dysphagia but 
a poor speech valve function. Radiological signs of disturbed bolus passage were common but the 
clinical impact of this seems to be low. 
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Sammanfattning på svenska   
Matstrupscancer beräknas vara den åttonde vanligaste cancerformen i världen, med över 460 000 nya fall per 
år. Sjukdomen diagnostiseras ofta i ett sent skede, är förknippad med stort lidande för den enskilda patienten 
och en allmänt dålig prognos. På grund av dessa omständigheter har behandlingen oftast en lindrande 
inriktning istället för en botande sådan. Huvudsyftet med lindrande behandling är framförallt att minska 
patienternas sväljningsbesvär. Denna avhandling omfattar olika frågeställningar kring behandling och 
omhändertagande av dessa patienter. 
De två vanligast förekommande lindrande behandlingsmetoderna idag, stentbehandling och brachy-
terapi, jämfördes i en randomiserad studie där 65 patienter med obotbar matstrupscancer deltog. Vi fann att 
stentbehandling gav en snabbare minskning av sväljningsbesvären jämfört med brachyterapi, samt att denna 
dessutom var mer kostnadseffektiv. Brachyterapi, å andra sidan, gav en mindre uttalad försämring av 
patienternas upplevda livskvalitet i övrigt och en likvärdig effekt vad gäller sväljningsbesvär från tre 
månader och framåt. Detta innebär att denna behandlingsmetod kan vara ett bättre alternativ för patienter 
med en längre förväntad överlevnadstid efter diagnos (Arbete I+II). 
För att utvärdera om patienternas överlevnadstid efter diagnos kan förutsägas analyserade vi kliniska 
data och livskvalitetsformulär (EORTC QLQ-C30 och QLQ-OES18) hos 96 patienter med obotbar mat-
strupscancer. I en univariat analys visade sig flera faktorer ha ett samband med överlevnadstiden. Dessa var 
Karnofsky Index, eventuell förekomst av metastaser, tumörstadium, datortomografiberäknad storlek av 
primärtumören samt 10 av de 25 skalorna och enskilda frågorna från livskvalitetsformulären. Då vi gick 
vidare med en multivariat analys fann vi dock att endast förekomst av metastaser samt fysisk funktion-, 
trötthets- och refluxskalorna var oberoende prediktorer för överlevnadstid. En intern validering av de funna 
prediktorerna visade en hög grad av tillförlitlighet hos den funna prognostiska modellen (Arbete III). 
Eventuell förekomst av psykisk ohälsa hos patienter med matstrupscancer har inte tidigare utvärderats. 
Med hjälp av HADS frågeformulär undersökte vi förekomsten av ångest- och depressionssjukdom hos 94 
patienter med olika tumörstadier av matstrupscancer, både vid diagnos och under ett års tid. Ångest- 
och/eller depressionssjukdom visade sig vara vanligt förekommande vid diagnos (42 % av patienterna), 
oavsett vad patienterna hade för sociodemografisk bakgrund, vilket tumörstadium de hade, eller vilken 
behandling de fick. Andelen patienter med ångestsjukdom minskade under de två första månaderna jämfört 
med vid diagnos (34 %), medan andelen patienter med depressionssjukdom var mer stabil över tiden (29 % 
vid diagnos). Depressionssjukdom visade sig vara mer vanligt förekommande hos dem som dog under 
studieåret jämfört med hos de som överlevde (Arbete IV). 
Slutligen gjorde vi en långtidsutvärdering av kliniska och funktionella parametrar hos patienter som 
genomgått strålning- och cytostatikabehandling följt av kurativt syftande operation med faryngo-laryngo-
esofagektomi och substitution med ett fritt jejunuminterponat. Resultaten vad beträffar överlevnad visade sig 
vara lovande jämfört med tidigare behandlingsalternativ. Patienterna uppgav överlag en relativt god livs-
kvalitet samt lindriga sväljningsbesvär, trots att deras röstförmåga med hjälp av talventil bedömdes vara 
dålig och att röntgenundersökning visade nedsatt bolustransport genom interponatet (Arbete V+VI). 
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Appendix 1  
ENGLISH 
 
 
EORTC QLQ-C30 (version 3)  
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
 
Please fill in your initials: bbbb 
Your birthdate (Day, Month, Year): cececdde 
Today's date (Day, Month, Year):  31 cececdde 
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
 
2. Do you have any trouble taking a long walk? 1 2 3 4 
 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
 
5. Do you need help with eating, dressing, washing  
 yourself or using the toilet? 1 2 3 4 
 
 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
 
8. Were you short of breath? 1 2 3 4 
 
9. Have you had pain? 1 2 3 4 
 
10. Did you need to rest? 1 2 3 4 
 
11. Have you had trouble sleeping? 1 2 3 4 
 
12. Have you felt weak? 1 2 3 4 
 
13. Have you lacked appetite? 1 2 3 4 
 
14. Have you felt nauseated? 1 2 3 4 
 
15. Have you vomited? 1 2 3 4 
 
16. Have you been constipated? 1 2 3 4 
 
 Please go on to the next page 
 
ENGLISH 
 
 
 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
17. Have you had diarrhea? 1 2 3 4 
 
18. Were you tired? 1 2 3 4 
 
19. Did pain interfere with your daily activities? 1 2 3 4 
 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
 
21. Did you feel tense? 1 2 3 4 
 
22. Did you worry? 1 2 3 4 
 
23. Did you feel irritable? 1 2 3 4 
 
24. Did you feel depressed? 1 2 3 4 
 
25. Have you had difficulty remembering things? 1 2 3 4 
 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
 
 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
 
29. How would you rate your overall health during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
 
 
© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
 
 
 
 
 
 
 
 
 
 
Appendix 2  
ENGLISH 
 
EORTC  QLQ – OES18 
 
 
Patients sometimes report that they have the following symptoms or problems. Please indicate the 
extent to which you have experienced these symptoms or problems  during the past week. Please 
answer by circling the number that best applies to you.   
 
During the past week: Not A Quite Very 
  at all little a bit much 
31. Could you eat solid food? 1 2 3 4 
32. Could you eat liquidised or soft food?  1 2 3 4 
33. Could you drink liquids?  1 2 3 4 
34. Have you had trouble with swallowing your saliva?  1 2 3 4 
35. Have you choked when swallowing?  1 2 3 4 
36. Have you had trouble enjoying your meals?  1 2 3 4 
37. Have you felt full up too quickly?  1 2 3 4 
38. Have you had trouble with eating?  1 2 3 4 
39. Have you had trouble with eating in front of other people?  1 2 3 4 
40. Have you had a dry mouth?  1 2 3 4 
41. Have you had problems with your sense of taste?  1 2 3 4 
42  Have you had trouble with coughing?  1 2 3 4 
43. Have you had trouble with talking?  1 2 3 4 
44. Have you had acid indigestion or heartburn?  1 2 3 4 
45. Have you had trouble with acid or bile coming into your mouth?  1 2 3 4 
46. Have you had pain when you eat?  1 2 3 4 
47. Have you had pain in your chest?  1 2 3 4 
48. Have you had pain in your stomach?  1 2 3 4 
 
 
 
 
 QLQ-OES18 Copyright 1999 EORTC Quality of life Group. All rights reserved.  
 
 
 
 
 
 
 
 
 
 
Appendix 3  
The Hospital Anxiety and Depression Scale (HADS) Questionnaire 
Instructions: Doctors are aware that emotions play an important part in most illnesses. If your doctor knows 
about these feelings he or she will be able to help you more. This questionnaire is designed to help your doctor 
know how you feel. Read each item and place a firm tick in the box opposite the reply which comes closest to 
how you have been feeling in the past week. Don't take too long over your replies: your immediate reaction to 
each item will probably be more accurate than a long thought out response. 
I feel tense or 'wound up':  
 
A  I feel as if I am slowed down:  D  
Most of the time  3   Nearly all of the time  3  
A lot of the time  2   Very often  2  
Time to time, occasionally  1   Sometimes  1  
Not at all  
 
0   Not at all  0  
I still enjoy the things I used to enjoy:  D   I get a sort of frightened feeling like 
'butterflies in the stomach':  
A  
Definitely as much  0   Not at all  0  
Not quite so much  1   Occasionally  1  
Only a little  2   Quite often  2  
Not at all  
 
3   Very often  3  
I get a sort of frightened feeling like 
something awful is about to happen:  
A  I have lost interest in my appearance:  D  
Very definitely and quite badly  3  Definitely  3  
Yes, but not too badly  2  I don't take as much care as I should  2  
A little, but it doesn't worry me  1  I may not take quite as much care  1  
Not at all  
 
0  I take just as much care as ever  0  
I can laugh and see the funny side of 
things:  
D   I feel restless as if I have to be on the 
move:  
A  
As much as I always could  0   Very much indeed  3  
Not quite so much now  1   Quite a lot  2  
Definitely not so much now  2   Not very much  1  
Not al all  
 
3   Not at all  0  
Worrying thoughts go through my mind: 
 
A  I look forward with enjoyment to things:  D  
A great deal of the time  3  A much as I ever did  0  
A lot of the time  2  Rather less than I used to  1  
From time to time but not too often  1  Definitely less than I used to  3  
Only occasionally  
 
0  Hardly at all  2  
I feel cheerful:  
 
D   I get sudden feelings of panic:  A  
Not at all  3   Very often indeed  3  
Not often  2   Quite often  2  
Sometimes  1   Not very often  1  
Most of the time  
 
0   Not at all  0  
I can sit at ease and feel relaxed:  A  I can enjoy a good book or radio or TV 
programme:  
D  
Definitely  0  Often  0  
Usually  1  Sometimes  1  
Not often  2  Not often  2  
Not at all  3  Very seldom  3  
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 
 
 
 
Karnofsky Performance Status Scale 
 
 
 
100  Normal, no complaints, no evidence of disease 
 90  Able to carry on normal activity, minor symptoms of disease  
 80  Normal activity with effort, some symptoms of disease  
 70  Cares for self: unable to carry on normal activity or active work  
 60  Requires occasional assistance but is able to care for needs  
 50  Requires considerable assistance and frequent medical care  
 40  Disabled, requires special care and assistance  
 30  Severely disabled, hospitalisation is indicated, death not imminent  
 20  Very sick, hospitalisation necessary, active treatment necessary  
 10  Moribund, fatal processes progressing rapidly  
   0         Dead 
 
